Johnson & Johnson (JNJ)
J&J CFO Joseph Wok on Q2 results: 2025 is shaping up to be better than what we'd thought
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, raising FY guidance, drug pipeline outlook, and more.
Johnson & Johnson Tops Q2 Estimates, Lifts Outlook for Sales and Profit
Johnson & Johnson (JNJ) on Wednesday lifted its full-year projections and reported second quarter results that beat estimates.
Johnson & Johnson (NYSE: JNJ) Live Earnings Updates: Will The Dividend Champion Deliver?
Johnson & Johnson reports before the bell today. The stock is popular in part thanks to its 3.3% dividend yield.
Johnson & Johnson's stock rallies after earnings beat and outlook raised, amid strength in heart and cancer treatments
Shares of Johnson & Johnson JNJ-1.05% climbed 1.6% in premarket trading Wednesday, after the drugmaker beat second-quarter earnings expectations and raised its full-year outlook, amid strength in sales of cancer treatments and heart health monitoring products.
Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales
Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on Wednesday as strong demand for its cancer drug, Darzalex, and strength in its medical device business helped it beat Wall Street expectations.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?
Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an important strategy, possibly improving the odds in your favor.
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream
These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
